Cargando…

Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer

We evaluated the survival benefit, safety, feasibility, and tolerability of dose-dense (DD) adjuvant chemotherapy with epirubicin and paclitaxel for women with node-positive primary breast cancer. Randomised patients (n=216) received DD or conventional-schedule (CS) chemotherapy. Dose-dense regimen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kümmel, S, Krocker, J, Kohls, A, Breitbach, G-P, Morack, G, Budner, M, Blohmer, J-U, Elling, D
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2006
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361407/ https://www.ncbi.nlm.nih.gov/pubmed/16622463 http://dx.doi.org/10.1038/sj.bjc.6603085

Ejemplares similares

Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy
por: Reinisch, Mattea, et al.
Publicado: (2023)

Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
por: Mirzaei, Hamid Reza, et al.
Publicado: (2013)

Dose-dense adjuvant chemotherapy for primary breast cancer
por: Fornier, Monica, et al.
Publicado: (2005)

Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
por: Puglisi, Fabio, et al.
Publicado: (2021)

Dose-Dense Docetaxel versus Weekly Paclitaxel following Dose-Dense Epirubicin and Cyclophosphamide as Adjuvant Chemotherapy in Node-Positive Breast Cancer Patients: A Retrospective Cohort Analysis
por: Khoshroo, Sara, et al.
Publicado: (2021)

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
por: Eiermann, W., et al.
Publicado: (2013)

HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients
por: Del Mastro, L, et al.
Publicado: (2005)

Efficacy, safety and proper dose analysis of PEGylated granulocyte colony-stimulating factor as support for dose-dense adjuvant chemotherapy in node positive Chinese breast cancer patients
por: Zhang, Fan, et al.
Publicado: (2017)

High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer
por: Brain, E, et al.
Publicado: (2011)

Adding Epoetin Alfa to Intense Dose-Dense Adjuvant Chemotherapy for Breast Cancer: Randomized Clinical Trial
por: Moebus, Volker, et al.
Publicado: (2013)

Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study
por: Shi, Tingyan, et al.
Publicado: (2019)

Adjuvant chemotherapy for colon carcinoma with positive lymph nodes: use and benefit in routine health care practice
por: Bouchardy, C, et al.
Publicado: (2001)

Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy
por: van Rossum, Annelot G.J., et al.
Publicado: (2017)

Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy
por: Nevala-Plagemann, Christopher, et al.
Publicado: (2018)

Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study.
por: Neri, B., et al.
Publicado: (1996)

Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical Cystectomy
por: Boström, Peter J., et al.
Publicado: (2016)

Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials
por: Zhou, Wenqi, et al.
Publicado: (2018)

Selection of breast cancer subtypes to improve benefits of intensive dose‑dense chemotherapy: A systematic meta‑analysis
por: Su, Dan, et al.
Publicado: (2023)

Efficacy and safety of dose-dense chemotherapy in urothelial carcinoma
por: Zhu, Chenjing, et al.
Publicado: (2017)

An observational study of dose dense chemotherapy with lipegfilgrastim support in early breast cancer
por: Rashed, Ahmed, et al.
Publicado: (2023)

Dose-dense chemotherapy for breast cancer: the story so far
por: Hudis, C
Publicado: (2000)

Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
por: Li, Qing, et al.
Publicado: (2020)

Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials
por: Loibl, Sibylle, et al.
Publicado: (2008)

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy
por: Fountzilas, George, et al.
Publicado: (2012)

Survival Benefit of Adjuvant Chemotherapy in Pulmonary Carcinoid Tumors
por: Sobash, Philip T., et al.
Publicado: (2022)

Is adjuvant chemotherapy better than neoadjuvant chemotherapy for those with node positive disease?
por: Zabell, Joseph, et al.
Publicado: (2018)

Adjuvant Chemotherapy in Node-Negative Advanced Gastric Cancer Patients
por: Su, Jian-wei, et al.
Publicado: (2022)

Dose-Dense Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Node-Positive Breast Cancer
por: Mirzaei, Hamid Reza, et al.
Publicado: (2014)

Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study
por: Blondeaux, Eva, et al.
Publicado: (2020)

Impressive Response to Dose-Dense Chemotherapy in a Patient with NUT Midline Carcinoma
por: Maur, Michela, et al.
Publicado: (2015)

Pneumocystis jirovecii in a patient on dose‐dense chemotherapy for early breast cancer
por: Khoo, Chloe, et al.
Publicado: (2019)

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer
por: De Placido, S, et al.
Publicado: (2005)

An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer.
por: Munro, A. J.
Publicado: (1995)

Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial
por: Jacquemier, Jocelyne, et al.
Publicado: (2011)

Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancer.
por: Miles, D. W., et al.
Publicado: (1994)

S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer.
por: Stål, O., et al.
Publicado: (1994)

Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy
por: Giacchetti, Sylvie, et al.
Publicado: (2022)

Benefit of adjuvant chemotherapy in patients with T4 UICC II colon cancer
por: Teufel, Andreas, et al.
Publicado: (2015)

Benefit of Adjuvant Traditional Herbal Medicine With Chemotherapy for Resectable Gastric Cancer
por: Lee, Yu Kyung, et al.
Publicado: (2018)

Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours
por: Fizazi, K, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_cdsp7hgkil23p12jgo8bdh194h